Navigation Links
SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193

leverages its proprietary technologies through multiple strategic partners, including the National Institutes of Health and TransTech Pharma, Inc. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

About the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a critical role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The information contained in this press release does not necessarily reflect the position or policy of the U.S. government, and no official endorsement should be inferred.

Forward-looking Statements

This Press Release contains or implies certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the safety or efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of SIGA. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to SIGA or its collaborators cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (b) SIGA or its collaborators will not obtain appropriate or necessary governmental approval
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Senate Passes Drug-Safety Reforms to Prevent Future Vioxx-type Disasters; House Urged to Act on Strong Drug Safety Bill
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SIGA Passes First Hurdle with Lassa Fever Antiviral
(Date:7/14/2014)... LONDON , July 14, 2014  VirtualScopics, ... (AIM: IXI) jointly announced today the formation of a ... Edward Ashton , Ph.D., chief scientific officer, VirtualScopics, ... members. "The formation of this joint Scientific ... commercial and operational alliance we signed with IXICO plc ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
Breaking Medicine Technology:VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... Calif., April 29, 2011 First Quarter ... by 321 institutions, up from 239 in Q4 2010 ... revenue Operational focus enables lower planned expense growth in ... by Astellas NGX-1998 Phase 2 clinical trial continues in ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that the company will ... Securities Research Conference San Francisco, CA, May 9-11, 2011 ... Dr. J. Joseph Kim, Ph.D., President & CEO May ...
Cached Medicine Technology:NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:7/14/2014)... NJ (PRWEB) July 14, 2014 ... established global leader in enterprise-class cloud management, governance, ... platforms, today announced AvePoint software will be available ... managed cloud specialist. , The hosting ... to offer the following AvePoint solutions to new ...
(Date:7/14/2014)... Washington DC (PRWEB) July 14, 2014 ... MessageSolution, an industry leader and Microsoft gold partner will ... network with Microsoft partners from the world and to ... all Microsoft platforms of Exchange email server, Office 365, ... DC from July 13 to 17, 2014. , “In ...
(Date:7/14/2014)... The Cabin Chiang Mai, Asia’s leading inpatient addiction ... website – a free comprehensive aftercare service for ... recovery wherever they live in the world. , The ... help them maintain their recovery after successfully completing primary ... treatment programme. As a chronic disease, addicts in recovery ...
(Date:7/14/2014)... According to the Blood Pressure Solution book ... that features a series of new information on high ... this book can help readers understand more about blood pressure. ... and effective methods to control hypertension naturally. ... Vkool, was penned by Ken Burge, a medical researcher and ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 "Medical ... every one of us. The Tri-Valley is a star ... Companies based in the region are working on amazing ... changing the face of medicine," according to Dale Kaye ... , To showcase some of the brilliant minds and ...
Breaking Medicine News(10 mins):Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4
... Medical Center have uncovered a protein in nerve cells that ... manufacture drugs that are capable of blocking chronic pain, by ... alleviating chronic pain have focused on the "second order" neurons ... brain. It's difficult to inhibit the activity of these neurons ...
... and Social Welfare’s Health Education Unit (HEU) in Swaziland ... than 40 communities in the country. // ... get the people thinking abut HIV AIDS through documentaries. ... Public Relations Officer Nana Mdluli said the campaign would ...
... the investigators at St. Jude Children's Research Hospital it was ... gland function during nursing can also initiate leukemias. // ... and fuses with another gene. The discovery of the normal ... the activity of its mutated form might be used in ...
... age 45 years or older who experience migraines with ... are at a higher risk for heart// attack, ischemic ... compared to women who do not report a migraine ... form of migraine, was not associated with increased risk ...
... at Buffalo researchers are conducting one of the ... ,The project is expected to provide ... quality is critical, such as in health-care facilities ... guest rooms in the Buffalo Niagara Marriott in ...
... China on Saturday reported a new outbreak of bird flu ... Xinjiang.// ,The national avian influenza laboratory tested samples ... stemming from an outbreak that began on July 14 near ... ,A total of 3,045 chickens died in the outbreak, and ...
Cached Medicine News:Health News:It may be possible to switch off acute pain 2Health News:Gene Responsible For Mammary Gland Function, When Mutated Results in Leukemias 2Health News:Gene Responsible For Mammary Gland Function, When Mutated Results in Leukemias 3Health News:Migraines with Aura Associated with Increased Risk for Cardiovascular Disease 2Health News:Scientists Put "Allergy-Friendly" Hotel Rooms to the Test 2Health News:Scientists Put "Allergy-Friendly" Hotel Rooms to the Test 3
... Protection Device features the ability to use ... lesion and a pre-loaded nitinol filter with ... Offering a fully rapid exchange system, the ... the indicated applications:, Carotid Indication - ,The ...
Clot-based Assay for Anti-FXa and/or Anti-Iia Therapies...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: